Skip to main
LNTH

Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings (LNTH) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 33%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Lantheus Holdings is experiencing a catalyst-rich year with multiple FDA approvals and upcoming PDUFA decisions. The company is focused on radiopharmaceutical products that assist in finding, fighting, and following diseases, making it a promising prospect for clinical settings. With a strong portfolio and expanding global reach, analysts have increased their estimates following a strong first quarter. As Lantheus prepares for a defense-to-offense shift in 2027, investors can expect to see significant revenue and EPS growth, making the stock an attractive opportunity.

Bears say

Lantheus Holdings is heavily dependent on two leading products that face competition from notable players and any disruptions to distribution or supply could significantly hurt the company's financial profile. Furthermore, reimbursement and regulatory risks could further impact the financials of the company. While the company does have a promising pipeline addressing the Alzheimer's diagnostic market, significant contributions are not expected for 2-3 years, and any interim data readouts may only generate investor interest at this time. Overall, Lantheus Holdings faces significant challenges in maintaining and growing its market presence, leading to a negative outlook on its stock.

Lantheus Holdings (LNTH) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 33% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lantheus Holdings (LNTH) Forecast

Analysts have given Lantheus Holdings (LNTH) a Buy based on their latest research and market trends.

According to 6 analysts, Lantheus Holdings (LNTH) has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $106.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $106.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lantheus Holdings (LNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.